In this Motley Fool Live video recorded on March 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss how Pfizer (PFE -1.03%), Moderna (MRNA 2.96%), and Johnson & Johnson (JNJ -1.22%) are faring in the U.S. vaccine rollout.
10 stocks we like better than Moderna Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of February 24, 2021
Corinne Cardina: We are now three months in to the vaccine rollout. Can't believe that. I remember when we were talking about, ''Who's going to have the first vaccine authorized?'' But at this point, we have three authorized vaccines in the U.S. Can you give us the latest update on the U.S. rollout and are we on a good trajectory?
Adria Cimino: Sure. Well, more than 47 million Americans are fully vaccinated now. That's 14% of the population. We also have more than 87 million with at least one dose. That's 26% of the population. If we want to see how each company is doing, we have numbers on that as well. We have 23 million fully vaccinated by Pfizer, 21 million fully vaccinated by Moderna, and 2 million by Johnson & Johnson. Of course, we have to keep in mind that Johnson & Johnson, they were most recently authorized, so they got in there a little bit later than the other two. And also it's a one-dose vaccine. So, President Biden bought enough doses of Pfizer and Moderna to vaccinate the entire U.S. population, but he still ordered more Johnson & Johnson. Johnson & Johnson, as you can see, is still being used. So really going after it very aggressively. The most recently announced goal is 200 million doses given in the first [100 days] of Biden's presidency -- that's the goal. We'll see if he can get there, but so far so good.